These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19807855)

  • 21. Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist.
    Fisher M
    Arch Neurol; 2006 Jan; 63(1):20-4. PubMed ID: 16401733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
    Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
    Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelet agents in stroke prevention: acute and long-term treatment strategies.
    Weber R; Weimar C; Diener HC
    Hamostaseologie; 2009 Nov; 29(4):326-33. PubMed ID: 19882077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
    Hankey GJ; Eikelboom JW
    Neurology; 2005 Apr; 64(7):1117-21. PubMed ID: 15824331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
    Kwon SU; Hong KS; Kang DW; Park JM; Lee JH; Cho YJ; Yu KH; Koo JS; Wong KS; Lee SH; Lee KB; Kim DE; Jeong SW; Bae HJ; Lee BC; Han MK; Rha JH; Kim HY; Mok VC; Lee YS; Kim GM; Suwanwela NC; Yun SC; Nah HW; Kim JS
    Stroke; 2011 Oct; 42(10):2883-90. PubMed ID: 21799173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
    Skliut M; Jamieson DG
    Curr Cardiol Rep; 2008 Feb; 10(1):9-16. PubMed ID: 18416995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
    Aw D; Sharma JC
    Postgrad Med J; 2012 Jan; 88(1035):34-7. PubMed ID: 22121248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases.
    Esagunde RU; Wong KS; Lee MP; Gan HY; Wong MC; Chang HM; Chen CL
    Cerebrovasc Dis; 2006; 21(4):242-6. PubMed ID: 16446537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of cilostazol on carotid intima-media thickness progression in patients with symptomatic intracranial atherosclerotic stenosis.
    Kim BJ; Rha JH; Kim SR; Kim DE; Kim HY; Lee JH; Bae HJ; Han MK; Kang DW; Ratanakorn D; Kim JS; Kwon SU
    J Stroke Cerebrovasc Dis; 2014; 23(5):1164-70. PubMed ID: 24315720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ["A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Part I: Protocol (author's transl)].
    Bousser MG; Eschwege E; Haguenau M; Lefauconnier JM; Touboul D; Touboul PJ
    Rev Neurol (Paris); 1981; 137(5):333-41. PubMed ID: 7027408
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical inquiries. What is the best management for patients who have a TIA while on aspirin therapy?
    Ahmed N; Coffey JB; Oh R
    J Fam Pract; 2006 Jul; 55(7):627-8. PubMed ID: 16822451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylaxis and acute therapy of arterial embolism with special reference to cerebral embolism.
    Tettenborn B; Krämer G; Erbel R
    Herz; 1991 Dec; 16(6):444-55. PubMed ID: 1765348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?
    Halkes PH; Algra A
    Cerebrovasc Dis; 2007; 24 Suppl 1():107-11. PubMed ID: 17971645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelets and stroke outcomes: state of the science.
    Meyer D
    Crit Care Nurs Clin North Am; 2009 Dec; 21(4):517-28. PubMed ID: 19951767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
    Diener HC
    Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transient ischemic attack: Part II. Risk factor modification and treatment.
    Simmons BB; Gadegbeku AB; Cirignano B
    Am Fam Physician; 2012 Sep; 86(6):527-32. PubMed ID: 23062044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.